|Systematic (IUPAC) name|
|Mol. mass||305.417 g/mol|
|(what is this?)|
UR-AK49 is a drug used in scientific research which acts as a potent antagonist for the Neuropeptide Y / Pancreatic polypeptide receptor Y4, and also as a partial agonist at the histamine receptors H1 and H2. UR-AK49 is a pure antagonist at Y4 with no partial agonist effects, and although it is only slightly selective for Y4 over the related Y1 and Y5 receptors, as the first non-peptide Y4 antagonist developed UR-AK49 is expected to be useful in the study of this receptor and its role in the body.
- Xie SX, Kraus A, Ghorai P, Ye QZ, Elz S, Buschauer A, Seifert R (June 2006). "N1-(3-cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (UR-AK57), a potent partial agonist for the human histamine H1- and H2-receptors". The Journal of Pharmacology and Experimental Therapeutics 317 (3): 1262–1268. doi:10.1124/jpet.106.102897. PMID 16554355.
- Ziemek R, Schneider E, Kraus A, Cabrele C, Beck-Sickinger AG, Bernhardt G, Buschauer A (2007). "Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence". Journal of Receptor and Signal Transduction Research 27 (4): 217–233. doi:10.1080/10799890701505206. PMID 17885919.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|